Having a combined regulatory and market access strategy is critical for a drug launch to be successful.
Marcus Deans, Mark A De Rosch and Emmanuelle Voisin
Emmanuelle M. Voisin, Founder and CEO
Emmanuelle Voisin founded Voisin Consulting Life Sciences (VCLS) in 1997. The firm has become a leading advisor to Biotech, Pharma and Medtech manufacturers for the development, registration and launch of innovative medical technologies across international markets. Emmanuelle Voisin has 30 years’ experience in drug development. Her expertise lies in non-conventional development strategies, maximizing the use of regulatory mechanisms and innovative approaches to drug development, to bring innovative technologies to patients.
Marcus Deans, Vice President Market Access & Pricing
Marcus leads the Global Market Access and Pricing Division within Voisin Consulting Life Science (VCLS) focusing on the development of Market Access strategies for Medicinal Products and Medical Devices (including in vitro diagnostics).
Mark De Rosch, Vice President Head of US Operations
Dr. Mark De Rosch is responsible for the management of projects involving the design and implementation of global regulatory strategies for the development, registration, and maintenance of pharmaceutical and biotechnology medicinal products. Mark is also heading the office in Cambridge, MA, USA. His expertise is in development of regulatory strategies for drugs and biologics, especially including orphan and pediatric diseases.
